Stock PHIO PHIO PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W5013

Market Closed - Nasdaq
Other stock markets
 21:30:00 05/07/2024 BST 		5-day change 1st Jan Change
5.245 USD +0.33% Intraday chart for Phio Pharmaceuticals Corp. -15.78% -23.32%
07-02 Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split MT
05-28 Phio Pharmaceuticals Corp. Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
NE
Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split
MT
Phio Pharmaceuticals Announces Reverse Stock Split
NE
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
NE
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762
AQ
Phio Pharmaceuticals Corp. Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762
CI
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
NE
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
NE
Phio Pharmaceuticals Files $100 Million Mixed Shelf
MT
Phio Pharmaceuticals Secures New Investor
AQ
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
AQ
Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study
MT
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
AQ
Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
CI
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
GL
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
AQ
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
AQ
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762
CI
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. News Phio Pharmaceuticals Corp.